• Sign In
  • Home
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
  • Policy
  • 2026 Election
  • Opinion
    • Editorials
    • Op-Eds
  • In Focus
  • Restoring America
  • Magazine
  • Watch
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • Examining Tax Reform
    • Fix TSCA
    • National Parks
    • Inside the Corn Belt
  • TWS Archive
Search
LogoWashington Examiner
Subscribe
LogoWashington Examiner
Sign in
Subscribe
  • News
    • Politics
      • Trump Administration
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Entertainment
    • Washington Secrets
  • Policy
    • Defense
    • National Security
    • Energy and Environment
    • Education
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space
  • 2026 Election
  • Trump Administration
  • IN FOCUS
  • Commentary
    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds
  • Restoring America
    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
  • Watch
  • Magazine
    • Magazine
    • Quarterly Briefing
    • Archives
    • Games
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • National Parks
    • Examining Tax Reform
    • Fix TSCA
    • Inside the Corn Belt
  • Newsletters
More
    Home Tags Pharmaceutical Industry

    Tag: Pharmaceutical Industry

    Lawmakers passed a bill that would let the FDA continue to collect user fees from drug and device makers, with the agency using that revenue to speed up approval of new products. (AP Photo/Andrew Harnik)
    Healthcare

    House advances FDA funding bill

    Robert King -
    July 12, 2017 6:40 pm
    0
    n the vacuum, Republicans are working to speed up approval of generic drugs in particular to offer more competition and lower prices. Democrats don't like that route because lower prices wouldn't be guaranteed.
    Healthcare

    Democrats disappointed Trump hasn’t worked to lower drug prices

    Robert King -
    June 26, 2017 4:01 am
    0
    It's no surprise that marketing works. (AP Photo/Sue Ogrocki, File)
    Op-Eds

    Are Big Pharma gifts to physicians an expensive problem, or a red herring?

    Brian Joondeph -
    June 23, 2017 12:00 pm
    0
    Rep. Elijah Cummings, D-Md., and Rep. Peter Welch, D-Vt., who met with President Trump earlier this year over tackling drug prices, are dismayed at the lack of action from the White House. (AP Photo/Pablo Martinez Monsivais)
    Healthcare

    House Democrats slam Trump ‘betrayal’ on drug prices

    Robert King -
    June 21, 2017 3:00 pm
    0
    This is the first time the FDA has taken steps to take a prescription painkiller off the market because of its risk for addiction. (AP Photo/Chris Post)
    Healthcare

    An FDA first: Agency asks drug company to take its opioid off the market

    Kimberly Leonard -
    June 8, 2017 9:34 pm
    0
    One of the moves Congress and the FDA are looking at is a loophole that major pharmaceutical companies use to stop generic makers from creating a cheaper copy.
    Healthcare

    FDA takes bigger role in lowering drug prices

    Robert King -
    June 5, 2017 4:01 am
    0
    The pharmaceutical giant has raised prices an average of 20 percent this year. (AP Photo/Richard Drew, File)
    Healthcare

    Pfizer hikes price on nearly 100 drugs, report says

    Robert King -
    June 2, 2017 7:57 pm
    0
    Representatives of drugmaker Mylan, which produces the allergy drug EpiPen, wants to meet with Sen. Chuck Grassley to discuss a subpoena threat over documents pertaining to Medicaid's rebate program. (AP Photo/Rich Pedroncelli, File)
    Healthcare

    EpiPen maker seeks meeting with Chuck Grassley over subpoena threat, report says

    Robert King -
    June 2, 2017 2:31 pm
    0
    In the last several years, stories of collusion, price gouging and cover-ups by industry executives have continued to unfold -- all designed to improve their bottom line at the expense of patients. (AP Photo/Mel Evans)
    Beltway Confidential

    4 ways Congress can put the brakes on rising pharmaceutical drug costs

    Kevin Campbell -
    June 1, 2017 4:17 pm
    0
    The HHS inspector general's office found that the government overpaid about $1.27 billion for the allergy antidote under the Medicaid rebate program. (AP Photo/Rich Pedroncelli, File)
    Healthcare

    Grassley: Mylan fleeced taxpayers $1.27 billion for EpiPen

    Robert King -
    May 31, 2017 7:38 pm
    0
    1...109110111...157Page 110 of 157
    LogoWashington Examiner
    Do Not Sell or Share My Personal Information
    Facebook
    Twitter
    Youtube

    NEWS

    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Washington Secrets
    • Entertainment
    • Sports

    POLICY

    • Defense
    • National Security
    • Energy
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space

    COMMENTARY

    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds

    RESTORING AMERICA

    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
    • WATCH
    • IN FOCUS
    • NEWSLETTERS
    • MAGAZINE ARCHIVE
    • Policies and Standards
    • Terms Of Service
    • Subscription Terms of Use
    • Privacy Policy
    • Your Privacy Choices
    • Transparency In Coverage
    • Advertise
    • Subscribe
    • Contact
    • Careers
    • Staff
    • About Examiner
    • Facebook
    • Twitter
    • © Copyright 2026. Washington Examiner. All Rights Reserved.